Search
Now showing items 31-36 of 36
Developing RAS-binding antibody-derived hit compounds
(Institute of Cancer Research (University Of London), 2023-09-27)
Exploring an oncolytic virus triggered PD-L1 response via immunoPET
(Institute of Cancer Research (University Of London), 2023-01-23)
Oncolytic virotherapy (OV) exploits viruses which preferentially infect and kill cancerous cells. Moreover, oncolytic viruses stimulate the tumour-immune microenvironment towards an inflammatory phenotype. Therefore, OV ...
The structure and mechanism of the EXD2 nuclease in DNA repair
(Institute of Cancer Research (University Of London), 2023-06-09)
DNA double strand breaks (DSBs) are one of the most toxic DNA lesions. They can jeopardise stability of the genome and lead to cancer development. There are two main pathways of DSB repair: homologous recombination (HR) ...
Investigating the role of EXD2 in end resection, genome stability, and cancer
(Institute of Cancer Research (University Of London), 2023-06-26)
DNA double-strand breaks (DSBs) are highly toxic lesions, so their accurate repair is required to maintain genome stability and prevent human diseases, including cancer. DSBs are repaired by two main pathways: "error-prone" ...
Deconstructing the soft tissue sarcoma matrisome and adhesome for drug target and biomarker discovery
(Institute of Cancer Research (University Of London), 2023-12-08)
Soft tissue sarcomas (STS) are a rare and diverse group of mesenchymal malignancies that present significant challenges in clinical management due to their extensive clinical and biological heterogeneity. STS have a dismal ...
Lysine-targeting covalent inhibitors
(Institute of Cancer Research (University Of London), 2023-12-14)
Targeted Covalent Inhibitors (TCIs) represent an increasingly important strategy in modern drug discovery. TCIs exploit high affinity, reversible ligands which are then modified with modestly-reactive electrophilic warheads ...